Schrodinger (SDGR) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Schrodinger (SDGR) has outperformed Zymeworks (ZYME) over the past year, gaining 39.2% versus a gain of 8.8%. Over five years, ZYME leads with a +34.1% price change compared with -42.0% for SDGR. Zymeworks is the larger company by market cap ($1.81 billion vs $1.72 billion), about 1.1 times the size.
Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -76.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | ZYME |
|---|---|---|
| Share price | $22.93 | $26.14 |
| Market cap | $1.72B | $1.81B |
| 1-day change | -12.95% | -2.68% |
| YTD return | +28.24% | -0.72% |
| 1-year return | +39.22% | +8.83% |
| 5-year return | -42.01% | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-0.79 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.87M | $105.97M |
| Revenue growth (YoY) | +23.29% | +38.87% |
| Net income (latest FY) | $-103.27M | $-81.13M |
| Gross margin | 55.74% | — |
| Operating margin | -65.23% | -87.34% |
| Net margin | -40.36% | -76.56% |
| 52-week high | $34.00 | $31.97 |
| 52-week low | $10.95 | $21.52 |
| Distance from 52-week high | -32.56% | -18.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.40% | +65.61% |
| Average volume | 2.08M | 1.09M |
| Shares outstanding | 65.91M | 68.70M |
| Employees | 850 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed ZYME by 30.4 percentage points over the past year.
- Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
- Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs +23.29%).
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
SDGR vs ZYME FAQ
Which is bigger, Schrodinger or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.72B for Schrodinger (SDGR).
Which stock has performed better over the past year, SDGR or ZYME?
SDGR returned +39.22% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.